Abstract
Persistent pain, a common clinical condition, could be caused by inflammation, tissue injury secondary to trauma or surgery, and nerve injuries. It is often inadequately controlled by current treatments, such as opioids and nonsteroidal anti-inflammatory drugs. The PDZ (Postsynaptic density 95, Discs large, and Zonula occludens-1) domains are ubiquitous protein interaction modules often found among multi-protein signaling complexes at neuronal synapses. Recent preclinical research shows that targeted disruption of PDZ domain-mediated protein interaction among N-methyl-Daspartate (NMDA) receptor signaling complexes significantly attenuates the development and maintenance of persistent pain without affecting nociceptive responsiveness to acute pain. PDZ domains at excitatory synapses may be new molecular targets for prevention and treatment of persistent pain. Here, we illustrate expression and distribution of the PDZ domain- containing proteins associated with NMDA receptors in the pain-related regions of the central nervous system, review the evidence for their roles in persistent pain states, and discuss potential mechanisms by which these PDZ domaincontaining proteins are involved in persistent pain.
Keywords: PSD-93, PSD-95, NMDA receptors, AMPA receptors, Trafficking, Spinal cord, Persistent pain, Chronic pain
Current Neuropharmacology
Title: PDZ Domains at Excitatory Synapses: Potential Molecular Targets for Persistent Pain Treatment
Volume: 4 Issue: 3
Author(s): Yuan-Xiang Tao and Roger A. Johns
Affiliation:
Keywords: PSD-93, PSD-95, NMDA receptors, AMPA receptors, Trafficking, Spinal cord, Persistent pain, Chronic pain
Abstract: Persistent pain, a common clinical condition, could be caused by inflammation, tissue injury secondary to trauma or surgery, and nerve injuries. It is often inadequately controlled by current treatments, such as opioids and nonsteroidal anti-inflammatory drugs. The PDZ (Postsynaptic density 95, Discs large, and Zonula occludens-1) domains are ubiquitous protein interaction modules often found among multi-protein signaling complexes at neuronal synapses. Recent preclinical research shows that targeted disruption of PDZ domain-mediated protein interaction among N-methyl-Daspartate (NMDA) receptor signaling complexes significantly attenuates the development and maintenance of persistent pain without affecting nociceptive responsiveness to acute pain. PDZ domains at excitatory synapses may be new molecular targets for prevention and treatment of persistent pain. Here, we illustrate expression and distribution of the PDZ domain- containing proteins associated with NMDA receptors in the pain-related regions of the central nervous system, review the evidence for their roles in persistent pain states, and discuss potential mechanisms by which these PDZ domaincontaining proteins are involved in persistent pain.
Export Options
About this article
Cite this article as:
Tao Yuan-Xiang and Johns A. Roger, PDZ Domains at Excitatory Synapses: Potential Molecular Targets for Persistent Pain Treatment, Current Neuropharmacology 2006; 4 (3) . https://dx.doi.org/10.2174/157015906778019473
DOI https://dx.doi.org/10.2174/157015906778019473 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
PDZ Domain-mediated Protein Interactions: Therapeutic Targets in Neurological Disorders
Current Medicinal Chemistry Synthesis and Evaluation of Novel Diazaspiro Hydantoins as Potential Anticonvulsants
Central Nervous System Agents in Medicinal Chemistry Drug Repurposing Approaches: Existing Leads for Novel Threats and Drug Targets
Current Protein & Peptide Science Evaluation of Antioxidant Activity of Phytol Using Non- and Pre-Clinical Models
Current Pharmaceutical Biotechnology From Axonal Transport to Mitochondrial Trafficking: What Can We Learn from Manganese-Enhanced MRI Studies in Mouse Models of Alzheimers Disease?
Current Medical Imaging Vagus nerve stimulation in treating depression: A tale of two stories.
Current Molecular Medicine Comparative Studies on Phospholipase A2 as a Marker for Gut Microbiota- liver-brain Axis in a rodent Model of Autism
Current Proteomics Synthesis, Experimental and Computational Studies of N-(4-amino-6-oxo- 1,6-dihydropyrimidin-5-yl)benzamide
Letters in Organic Chemistry Brain Network Connectivity Mediates Education-related Cognitive Performance in Healthy Elderly Adults
Current Alzheimer Research Relationship Between Susceptibility to DMCM-Induced Generalized Motor Convulsions and Low-Affinity [3H]-Ouabain Binding in Membranes in Rat Brain
Current Molecular Pharmacology Drug-induced Inhibition and Trafficking Disruption of ion Channels: Pathogenesis of QT Abnormalities and Drug-induced Fatal Arrhythmias
Current Cardiology Reviews Potentials of ES Cell Therapy in Neurodegenerative Diseases
Current Pharmaceutical Design Ultrasound-promoted Organic Synthesis - A Recent Update
Current Organic Chemistry Fibromyalgia: Mechanisms, Current Treatment and Animal Models
Current Pharmaceutical Biotechnology From Cannabis to Cannabidiol to Treat Epilepsy, Where Are We?
Current Pharmaceutical Design An Insight into Molecular Mechanisms and Novel Therapeutic Approaches in Epileptogenesis
CNS & Neurological Disorders - Drug Targets Small Molecule Natural Products and Alzheimer’s Disease
Current Topics in Medicinal Chemistry HHT: A Rare Disease with A Broad Spectrum of Clinical Aspects
Current Pharmaceutical Design Molecular Cytogenetics of Autism
Current Genomics Supplements, Diets and Other Complementary and Alternative Interventions in Adolescent Mental Health
Adolescent Psychiatry